US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 09:51:53 Source:sportViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:UK court rules that extension of UK police powers to intervene in protests is unlawful
Next:Hush money trial: Trump witness Costello back on the stand after admonishment
You may also like
- Guardians ruin Francisco Lindor's Cleveland homecoming, trip Mets 3
- Campaign to Ensure More Children Insured
- Rural Tourism Sees Robust Growth
- Unique Party Held for Upcoming Tibetan New Year
- Protesters against war in Gaza interrupt Blinken repeatedly in the Senate
- With Ice, Snow, Hospitality, Harbin Becomes Brightest Star of Tourism in China
- Curling Mixed Doubles Round Robin Session 14 at Gangwon 2024: New Zealand vs. China
- Push for More Parental Care Leave Gathers Pace
- Kentucky congressman expects no voter fallout for his role in attempt to oust House speaker